Solu-Medrol

Methylprednisolone Na succinate

Endocrine, rheumatic & hematologic disorders; collagen & immune complex diseases, dermatologic, ophth, GI, resp diseases ie, exacerbations of COPD & neoplastic disease; allergic ie, bronchial asthma & edematous states; acute exacerbation of multiple sclerosis; tuberculous meningitis w/ subarachnoid or impending block; trichinosis w/ neurologic or myocardial involvement; cerebral edema from primary or metastatic tumors; organ transplantation; prevention of nausea & vomiting associated w/ cancer chemotherapy; acute spinal cord injury (treatment should begin w/in 8 hr of injury).

IV infusion or IM Adjunct in life-threatening conditions 30 mg/kg IV over 30 min, may be repeated 4-6 hrly for up to 48 hr. Rheumatic disorders 1 g/day for 1-4 days or 1 g/mth for 6 mth, IV pulse dosing over at least 30 min, may be repeated if improvement has not occurred w/in a wk. SLE 1 g/day for 3 days, IV pulse dosing over at least 30 min, may be repeated if improvement has not occurred w/in a wk. Multiple sclerosis 1 g/day for 3-5 days as IV pulse dosing over at least 30 min, may be repeated if improvement has not occurred w/in a wk. Edematous states 30 mg/kg every other day for 4 days or 1 g/day for 3, 5 or 7 days, IV pulse dosing over at least 30 min, may be repeated if improvement has not occurred w/in a wk. Terminal cancer 125 mg/day IV for up to 8 wk. Prevention of nausea & vomiting associated w/ cancer chemotherapy: Mild to moderate emetogenic chemotherapy 250 mg IV over at least 5 min 1 hr prior to chemotherapy; repeat dose at the initiation of chemotherapy & at time of discharge. Severely emetogenic chemotherapy 250 mg IV over at least 5 min w/ appropriate doses of metoclopramide or butyrophenone 1 hr prior to chemotherapy; repeat dose at the initiation of chemotherapy & at the time of discharge. Acute spinal cord injury 30 mg/kg as an IV bolus over 15 min followed by a 45-min pause, then continuous IV infusion of 5.4 mg/kg/hr for 23-47 hr. Pneumocystis carinii pneumonia in patients w/ AIDS 40 mg IV every 6-12 hr w/ gradual tapering over a max of 21 days or until the end of pneumocystis therapy. Exacerbation of COPD 0.5 mg/kg or 125 mg IV 6 hrly for 72 hr. Total treatment period: 2 wk. Adjunctive therapy in other indications Initially 10-500 mg IV, depending on clinical condition. Ped Min dose: 0.5 mg/kg 24 hrly.

Hypersensitivity. Systemic fungal infections. Intrathecal & epidural route. Co-administration w/ live or live attenuated vaccines.

Infectious complications. Co-administration w/ immunosuppressive agent, aspirin or NSAID. Latent TB or tuberculin reactivity. Septic shock patient; unusual stress patient. HPA suppression. Abrupt discontinuance of glucocorticoids. Cushing's disease. Hypothyroidism. Diabetes. Psychic derangement, existing emotional instability or psychotic tendency, seizure disorder, myasthenia gravis. Ocular herpes simplex. CHF. HTN. Non-specific ulcerative colitis. Patients w/ diverticulitis. Fresh intestinal anastomoses. Active or latent peptic ulcer. Neuromuscular transmission disorder. Renal insufficiency. Head injury. Rapid administration of large IV doses of methylprednisolone Na succinate. Prolonged corticosteroid administration in infants & childn. Ped, premature & low-birth wt infant.

Opportunistic infection, drug hypersensitivity including anaphylactic or anaphylactoid reaction, cushingoid, hypopituitarism, steroid w/drawal syndrome, lipomatosis, Na & fluid retention, hypokalaemic alkalosis, dyslipidemia, impaired glucose tolerance, increased insulin requirement or oral hypoglycemic agents in diabetes, negative nitrogen balance, increased blood urea & appetite, affective & psychotic disorder, confusional state, insomnia, irritability, epidural lipomatosis, increased intracranial pressure w/ papilloedema (benign intracranial HTN), convulsion, amnesia, cognitive disorder, dizziness, headache, exophthalmos, glaucoma, cataract, central serious chorioretinopathy, vertigo, congestive cardiac failure, arrhythmia, HTN, hypotension, hiccups, gastric haemorrhage, intestinal perforation, peptic ulcer w/ possible perforation & hemorrhage, pancreatitis, peritonitis, ulcerative oesophagitis, oesophagitis, abdominal pain & distention, diarrhea, dyspepsia, nausea, hepatitis, angioedema, peripheral oedema, ecchymosis, petechiae, skin atrophy, striae & hypopigmentation, hirsutism, rash, erythema, pruritus, urticaria, acne, hyperhidrosis, osteonecrosis, pathological fracture, growth retardation, muscle atrophy, myopathy, osteoporosis, neuropathic arthropathy, arthalgia, myalgia, muscular weakness, irregular menstruation, impaired wound healing, inj site reaction, fatigue, malaise, K loss, increase in ALT (SGPT), AST (SGOT), blood alkaline phosphatase, IOP & urine Ca, decrease in carbohydrate tolerance & blood K, suppression of reactions to skin tests, tendon rupture & spinal compression fracture.

INH, rifampin, oral anticoagulants, carbamazepine, phenobarb, phenytoin, neuromuscular blockers eg, pancuronium, vecuronium, anticholinesterases, antidiabetics, aprepitant, fosaprepitant, itraconazole, ketoconazole, HIV-PIs; indinavir, ritonavir, aminoglutethimide, diltiazem, ethinylestradiol/norethindrone, grapefruit juice, cyclosporine, cyclophosphamide, tacrolimus, clarithromycin, erythromycin, troleandomycin, high-dose aspirin & K-depleting agents. 

Corticosteroid Hormones

H02AB04 - methylprednisolone ; Belongs to the class of glucocorticoids. Used in systemic corticosteroid preparations.

S